Translate page

iCMLf

Alliance

    Highlights from ASH 2016:
    3 CML experts give their personal perspectives

    This independent educational resource is supported by a grant from Novartis Oncology

    Perspectives on molecular monitoring in CML from 
    Associate Professor Susan Branford, PhD
    Center for Cancer Biology
    SA Pathology, Adelaide, Australia

    • Treatment-free remission studies including an update of the EURO-SKI trial
    • New data on optimal timing for monitoring patients after stopping therapy
    • Additional chromosomal abnormalities and their impact on prognosis
    • Next generation sequencing technologies 

     {rscomments off}